Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism

Iris Lim1 · Russ Chess-Williams1

Received: 10 February 2022 / Accepted: 13 April 2022 / Published online: 21 April 2022
© The Author(s) 2022

Abstract
The β3-agonist mirabegron is thought to induce relaxation of the detrusor muscle, contributing to the improvement of overactive bladder symptoms. There has been recent interest in purposing mirabegron as a medical expulsive therapy drug to improve the passage of smaller kidney stones by relaxing the ureteral smooth muscles. The aim of this study was to determine the effects of mirabegron on the activity of the ureter. Additionally, we investigated the receptor and mechanisms through which mirabegron exerts these effects. In vitro agonist-induced responses of isolated porcine distal ureteral tissues were measured in the absence and presence of mirabegron in organ bath experiments. The responses were expressed as frequency, area under the curve and maximum amplitude. Mirabegron at concentrations of 100 nM and lower failed to suppress phenylephrine- or 5-HT-induced contractions in the porcine ureteral strip. Mirabegron at 1 μM and 10 μM produced a rightward shift of phenylephrine concentration–response curves in these tissues. This effect of mirabegron (10 μM) was not present in 5-HT concentration–response curves. The mirabegron effect on phenylephrine-induced contractions was also not abolished by β-adrenoceptor antagonist SR 59230A (10 μM), β-adrenoceptor antagonist propranolol (10 μM), α2-adrenoceptor antagonist yohimbine (30 nM), and nitric oxide synthase inhibitor l-NNA (10 μM). The present results show that mirabegron suppresses ureteral contractile responses in the porcine ureter via α1-adrenoceptor antagonism, since their effects were not present when the tissues were contracted with 5-HT. Furthermore, the inhibitory effects by mirabegron were not affected by β3-adrenoceptor antagonists.

Keywords α1-adrenoceptor · Porcine · Smooth muscle contraction · Ureter · β-adrenoceptor · Mirabegron

Introduction
Urolithiasis, or known as urinary stones, is a widespread condition worldwide affecting up to 10% of the population, with its healthcare burden cost and prevalence continuing to increase (Gillams et al. 2021). While stones that are smaller in size can usually pass to the bladder spontaneously with urine, larger stones might lodge in the ureter. This usually results in a pressing pain, known as ureteral or renal colic, which is frequently presented clinically in patients. Ureteral colic is proposed to be induced by elevated intrarenal pressure which is caused by the constriction of the ureteral smooth muscle wall (Campschroer et al. 2018). In cases of smaller stones, medical expulsive therapy can be recommended with the aim of promoting stone passage by reducing constriction and relaxing the ureteral tube. Since the introduction of medical expulsive therapy, tamsulosin, the α1-adrenoceptor antagonist is the most commonly used drug and continues to be the recommendation of most urological associations to improve small stone passage (Assimos et al. 2016). This is not unexpected, as the main innervation of the ureter is controlled by the adrenergic system where the net effect of noradrenaline application results in contraction of the smooth muscles via α1-adrenoceptor stimulation (Forman et al. 1978).

The use of a β3-adrenoceptor agonist mirabegron for the management of overactive bladder has been shown to be effective in the recent years, reducing both urinary frequency and urgency, with low incidence of side effects and thus, high tolerability profile (Takahashi et al. 2022). Mirabegron is proposed to function by activating the
β3-adrenoceptors in the human detrusor smooth muscle, inducing a relaxation during the storage phase of micturition (Svalo et al. 2013; Takasu et al. 2007). Previous studies have also shown that mirabegron is capable of relaxing other smooth muscle tissues of the urinary tract like the urethra and the prostate (Alexandre et al. 2016; Huang et al. 2021). Given the proximity of the ureter, particularly the distal section, to these organs, there has been recent interest in purposing mirabegron as a medical expulsive therapy alternative to tamsulosin to promote stone passage (Tang et al. 2021). This study aimed to investigate the effects of mirabegron on ureteral contractions in isolated porcine tissues. This animal model has been shown in a previous study to be a reliable pharmacological and physiological model, similar to that of the healthy human ureter (Lim et al. 2020). Additionally, this study also aimed to investigate the mechanisms through which mirabegron exerts its effects on this tissue.

Materials and methods

Tissue specimen origin and preparation

The urinary bladders (with ureters and urethra attached) of 6-month-old female Landrace pigs were obtained from a local abattoir and placed in ice-cold Krebs-bicarbonate solution (4 °C) composed of NaCl (118.4 mM), KCl (4.7 mM), NaHCO3 (24.9 mM), glucose (11.7 mM), CaCl2 (1.9 mM), MgSO4 (1.2 mM) and KH2PO4 (1.2 mM) and immediately transported to the laboratory within 2 h. The distal segment of the ureter was isolated and dissected into 4 mm long tube sections. These rings were cut opened (where the full diameter measures 6–7 mm) and suspended longitudinally. Paired tissues strips were utilised in the experiments of this study where adjacent tube sections of the same ureter were set up in separate organ baths and considered to be ‘paired’. The distal ureter was examined, as this is the most common site for urinary stone lodgement clinically (El-Barky et al. 2014). The urothelium and lamina propria were left intact with the smooth muscle strips in all experiments.

The tissue strips were mounted longitudinally under approximately 1.5 g tension in 8 ml EZ-Bath organ baths (Global Towns Microtechnology, Sarasota, FL, USA) containing Krebs-bicarbonate solution. The baths were maintained at 37 °C and continuously gassed with 95% O2 and 5% CO2 at pH 7.4. Equilibration of tissue strips was performed for 1 h with fresh solution washouts every 15 min, before addition of any drug. The isometric tension developed by the tissues was recorded via a Powerlab recording system and the LabChart software (ADInstruments, Castle Hill, NSW, Australia).

Relaxatory effects of mirabegron on pre-contracted ureter

To investigate potential relaxatory effects of β3-adrenoceptor agonist mirabegron, paired tissue strips were first pre-contracted with α1-adrenoceptor agonist phenylephrine (300 μM) or 5-hydroxytryptamine (5-HT) (100 μM). Upon generation of a consistent pattern of contractile activity (approximately 10 min), mirabegron was cumulatively added to one tissue strip (100 nM–1 mM), while the other strip acted as a vehicle and time control. These experiments were then repeated in the presence of β-adrenoceptor antagonist SR 59230A (10 μM).

Effects of mirabegron on agonist concentration–response

To determine the effects of mirabegron on phenylephrine and 5-HT-induced concentration–response, paired tissues strips were set up. Mirabegron (100 nM, 1 μM or 10 μM) was added to one tissue strip, while the other acted as a vehicle control. Following a 30-min incubation, tissue response to increasing concentrations of either phenylephrine (100 nM–1 mM) or 5-HT (300 nM–300 μM) was measured.

Mechanisms of mirabegron-induced effects

In this part of the study, we aimed to investigate the receptor and/or mechanism through which mirabegron mediates its effects on the phenylephrine responses in the distal ureteral tissue. Pairing tissue strips from the same ureter, we incubated all tissues with either β-adrenoceptor antagonist SR 59230A (10 μM), β1- and β2-adrenoceptor blocker propranolol (10 μM), nitric oxide synthase inhibitor L-NNA (10 μM) or α2-adrenoceptor antagonist yohimbine (30 nM) for 30 min. Simultaneously, one of the paired strips was also incubated with mirabegron (10 μM) and concentration–response curves to phenylephrine were then performed.

Data and statistical analysis

In response to phenylephrine or 5-HT, isolated ureteral strips developed bursts of phasic contractile activity (Fig. 1). These contractile responses appeared to increase in frequency (contractions per minute) in a concentration-dependent manner. The amplitude of the phasic contractions did not appear to have an observable pattern in this study. Area under the curve (AUC) by weight was calculated to determine the overall contractile responses of the ureter, accounting for changes in both amplitude and frequency of contractions.
The frequency and AUC were measured over 5 min for each variable. The highest amplitude of the phasic contractions by tissue weight was also assessed.

The GraphPad Prism software (GraphPad, San Diego, CA, USA) was used to perform all statistical analysis and graphical representation. All data were expressed as mean ± SD of ‘n’ preparations, where ‘n’ is the number of animals. For each experiment, a sample size of n = 8 was used. However, occasionally, some tissues strips were not responsive or minimally responsive and these were considered outliers. This study is deemed to be of an explorative nature rather than a hypothesis-design study (Michel et al. 2020).

pEC50 values were calculated as the negative logarithm of the agonist concentration required to achieve 50% of maximal contractile response. Concentration–response curves were compared using two-way ANOVA, while pEC50 and maximum amplitude values, using two-tailed, paired Student’s t tests, where p < 0.05 was considered statistically significant.

Drugs and chemicals used

The chemicals used for the Krebs-bicarbonate solution were of analytical grade and purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). (R)-(−)-Phenylephrine hydrochloride, 1-(2-Ethylphenoxy)-3-[[1(S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol hydrochloride (SR 59230A), propranolol hydrochloride, Nω-Nitro-L-arginine (l-NNA) and yohimbine hydrochloride were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia). Serotonin hydrochloride (5-HT) was obtained from Abcam (Melbourne, VIC, Australia) and mirabegron from Tocris (Noble Park, Victoria, Australia). All drugs were dissolved in distilled H2O except mirabegron and yohimbine which were dissolved in DMSO (final concentration of DMSO never exceeded 0.3%). All experiments were performed with a vehicle control where an equivalent amount of solvent (distilled H2O or DMSO) was added into the baths with control strips.

Results

General observations

All porcine ureteral strips (mean weight, 0.0323 ± 0.0021 g, n = 132) were allowed to equilibrate to a passive tension of 1.53 g ± 0.15 g. During the equilibration period, none of the distal ureteral strips developed spontaneous contractions where they all remained quiescent in the absence of agonists. When quiescent tissues were subjected to phenylephrine (300 μM) or 5-HT (100 μM), they developed bursts of phasic contractions, as seen in Fig. 1. Increasing concentrations of phenylephrine (100 nM–1 mM) and 5-HT (300 nM–300 μM) resulted in increase in frequency and general phasic contractility measured as area under the curve (AUC) in a concentration-dependent manner. The amplitude of these phasic contractions was not agonist concentration-dependent and thus, expressed as maximum amplitude. Phenylephrine (300 μM) and 5-HT (100 μM) resulted in phasic contractions that had similar maximum amplitude values (phenylephrine, 1.91 ± 0.18 N/g; 5-HT, 1.81 ± 0.20 N/g).

Relaxatory effects of mirabegron on ureteral contractility

Upon generation of consistent phasic contractility induced by phenylephrine (300 μM), increasing concentrations of mirabegron (100 nM–1 mM) reduced the frequency and general contraction expressed as AUC of the contractions. However, when compared to the time and vehicle control, only high concentrations of mirabegron (10 μM and above) resulted in significant reduction of frequency (Fig. 2A), while reduction of AUC and amplitude contractions required even higher concentrations of the drug (100 μM and above, Figs. 2B–2C). When the experiment was repeated in the presence of SR 59230A (10 μM), similar findings were observed (Figs. 3A–3C). When pre-contracted with 5-HT (100 μM), mirabegron did not attenuate frequency of the ureteral contractile responses (Fig. 2D) at any concentration tested and only reduced AUC and maximum amplitude of contractile responses at 100 μM and above. Similar observations were found when these experiments were repeated in the presence of SR 59230A (10 μM) (Figs. 3D–3F).

Effects of mirabegron on agonists-induced concentration–response

Mirabegron, at 1 μM and 10 μM, produced a rightward shift of the phenylephrine concentration–response curves expressed as frequency (1 μM, p = 0.0351; 10 μM, p < 0.0001) and AUC (1 μM, p = 0.0036;
Fig. 2 Concentration–response to mirabegron (hollow circles, solid lines) in porcine isolated distal ureteral tissue vs paired time and vehicle control (filled circles, dotted lines). Reduction in contractility was calculated relative to the initial contraction produced by A–C phenylephrine (300 µM) and D–F 5-HT (100 µM) in each tissue strip. Results are presented as mean ± SD (n = 6–8).

Fig. 3 Concentration–response to mirabegron (hollow circles, solid lines) in porcine isolated distal ureteral tissue vs paired time and vehicle control (filled circles, dotted lines) in the presence of SR59230A (10 µM). Reduction in contractility was calculated relative to the initial contraction produced by A–C phenylephrine (300 µM) and D–F 5-HT (100 µM) in each tissue strip. Results are presented as mean ± SD (n = 7–8).
10 μM, p < 0.0001) in the porcine distal ureteral tissues (Figs. 4D–4E, 4G–4H, Table 1). Lower concentration of mirabegron (100 nM) was not capable of producing this shift in the phenylephrine concentration–response curve. Mirabegron (10 μM) did not shift the 5-HT concentration–response curves expressed as frequency and AUC (Figs. 5D–5E). The maximum frequency, AUC and amplitude of phenylephrine- and 5-HT-induced contractile responses were reduced by mirabegron, at 10 μM (Figs. 4G–4I, 5D–5F).

**Table 1** Mirabegron effects on the potency (pEC50) of phenylephrine. Results are presented as mean±SD of ‘n’ preparations (paired Student’s t tests, *p < 0.05 vs control)

| Concentration | Frequency response | AUC response | n   |
|---------------|--------------------|--------------|-----|
|               | Control            | Mirabegron   | Control | Mirabegron |
| 100 nM        | 4.10±0.77          | 4.03±1.11    | 4.16±0.40 | 4.15±0.69   | 7 |
| 1 μM          | 4.14±0.51          | 3.60±0.49*   | 4.18±0.51 | 3.63±0.37a  | 6 |
| 10 μM         | 4.15±0.61          | 3.07±0.56**a| 4.20±0.40 | 3.07±0.93**a| 7 |

*pEC50 values for 10 μM are estimated as the maximum responses were significantly reduced
Mediation of mirabegron-induced effects

In the presence of β3-adrenoceptor antagonist SR 59230A (10 μM), the mirabegron effects on phenylephrine concentration responses were similar to that observed in the absence of the antagonist, where pEC50 values are significantly reduced (Table 2), and maximum frequency (p < 0.0001), AUC (p < 0.0001) and amplitude decreased in the presence of mirabegron (10 μM) (Figs. 5A–5C). Mirabegron effect was also unaffected when the experiments were repeated in the presence of β1- and β2-adrenoceptor blocker propranolol (10 μM), nitric oxide synthase inhibitor l-NNA (10 μM), and α2-adrenoceptor antagonist yohimbine (30 nM) (Table 2).

Discussion and conclusions

While detrusor and urethral tissue strips from the same species usually exhibit tonic contractions in response to common agonist drugs (Folasire et al. 2017; Kang et al. 2015), studies from our laboratory on the ureter have reported on the complexity of the contractile activity in this tissue (Lim et al. 2020). In this study, we report on all the components

Table 2 Mirabegron (10 μM) effects on the potency (pEC50) of phenylephrine in the presence of SR 59230A (10 μM), propranolol (10 μM), l-NNA (10 μM) and yohimbine (30 nM). Results are presented as mean ± SEM of ‘n’ preparations (paired Student’s t tests, *p < 0.05 vs control)

|                        | Frequency response |                      |  | AUC response |                      |  |
|------------------------|--------------------|----------------------|  |             |----------------------|  |
|                        | Control            | Mirabegron           |  | Control      | Mirabegron           |  |
| SR 59230A (10 μM)      | 4.21 ± 0.40        | 3.10 ± 1.11**        |  | 4.25 ± 0.66  | 3.01 ± 1.23**        |  |
| Propranolol (10 μM)    | 4.06 ± 0.57        | 3.01 ± 0.99**        |  | 4.11 ± 0.59  | 3.00 ± 0.96**        |  |
| l-NNA (10 μM)          | 4.28 ± 0.99        | 2.99 ± 1.30**        |  | 4.29 ± 0.75  | 3.12 ± 0.99**        |  |
| Yohimbine (30 nM)      | 4.15 ± 0.39        | 3.05 ± 0.64**        |  | 4.16 ± 0.56  | 3.01 ± 0.42**        |  |

*pEC50 values are estimated as the maximum responses were significantly reduced
of this phasic activity, including frequency, amplitude and AUC, to ensure we can capture the complexity of the response from this tissue. Because the ureter mainly receives adrenergic stimulation, it is hypothesised that contractile activity stimulated by adrenoceptor agonists is more relevant physiologically, particularly in ureteral peristalsis (Zaitouna et al. 2017). The present study investigated the effects of mirabegron on ureteral contraction and the mechanisms associated. The results of this study suggest that in the ureter, (a) mirabegron, at β3-adrenoceptor selective concentrations, does not relax the tissue, (b) mirabegron, at 1 μM and higher, produces a rightward shift of phenylephrine concentration–response curve, and (c) this mirabegron-induced rightward shift does not involve β-adrenoceptors, α2-adrenoceptors or nitric oxide production.

When pre-contracted with agonists, mirabegron at low concentrations where it selectively activates β3-adrenoceptor (Igawa and Michel, 2013) did not produce significant relaxatory effects on the ureter. Although previous studies have indicated that this receptor subtype is present in the human ureter and has the potential to be a significant target for medical expulsive therapy (Matsumoto et al. 2013; Shen et al. 2017), our current findings suggest otherwise. Binding assays suggest Ki value of 2.5 nM for human β3-adrenoceptors, if determined in Chinese Hamster Ovary cells stably addressing human β-adrenoceptor (Tasler et al. 2012). Nevertheless, mirabegron, at concentrations of 1μM and higher, was shown to reduce the frequency, AUC and amplitude of these phenylephrine-induced contractions. Additionally, when we pre-contracted the tissues with a different agent (5-HT), this attenuation effect was not visible. Therefore, we hypothesised that the mirabegron-induced ureteral relaxations were due, at least partly, to α1-antagonism as this has been proposed in other tissues of the urinary tract (Michel 2020).

Our agonist concentration response studies showed that the presence of mirabegron, at 1 μM and higher, was capable of antagonising phenylephrine-induced contractility. This is not surprising, as previous studies have reported that similar concentrations of mirabegron antagonises other receptors including α1-adrenoceptor stimulation in the urethra (Alexandre et al. 2016) and prostate (Alexandre et al. 2016; Huang et al. 2021), and muscarinic receptors in the pig and human detrusor (Maki et al. 2019; Yamada et al. 2021). Additionally, during its regulatory submission, it was also indicated that this drug potentially antagonises α1-adrenoceptors (U.S. Food and Drug Administration 2012). In our ureteral study, mirabegron, at 10 μM, also decreased maximum contractions which was not observed in the urethra (Alexandre et al. 2016) or prostate (Huang et al. 2021). Due to this decrease in maximum contractions, we could only calculate apparent pA2 values using shifts at the lower part of the concentration curves. The apparent pA2 values were calculated using the rightward shifts of the phenylephrine curves in the presence of 1 and 10 μM range from 6.1 to 6.5. This affinity estimate is comparable with values reported from radioligand binding studies with human recombinant α1A- and α1D-adrenoceptors which was 6.0 (Alexandre et al. 2016). The Ki values of mirabegron for α1-q-adrenoceptor subtypes from competition assays indicated that binding affinities from high to low are as follows: α1A (0.437 μM) > α1D (1.8 μM) > α1H (26 μM) (Alexandre et al. 2016). In line with our suggestion, α1A-adrenoceptor is known to be the functionally predominant subtype for α1-adrenergic contractions in the human ureter (Sasaki et al. 2011).

Although the involvement of β3-adrenoceptors at this point appeared unlikely, we confirmed that the β-adrenoceptor antagonist SR 59230A did not abolish this mirabegron effect. A previous study on the human atrial tissue showed that mirabegron could activate β1-adrenoceptors via an indirect mechanism (Mo et al. 2017). To confirm that the other β-adrenoceptor subtypes and α2-adrenoceptors are not involved, we also repeated the experiments in the presence of propranolol and yohimbine. Our findings suggest these receptors are not involved. Additionally, β3-adrenoceptor activation by mirabegron in the bladder has been shown to increase nitric oxide production to relax the detrusor muscle (Imran et al., 2013). To further cement that we do not believe this receptor and mechanism is involved, we demonstrated that the nitric oxide synthase inhibitor l-NNA did not alter the mirabegron-induced effects.

We also investigated whether mirabegron antagonises 5-HT concentration responses. This was not evident from our findings, which further suggests that the effects of mirabegron in our experiments were largely limited to α1-adrenoceptor antagonism. Interestingly, mirabegron (10 μM) reduced the maximum frequency, AUC and amplitude of contractile responses to 5-HT. We believe that at high concentration of 5-HT, α1-adrenoceptors are also activated to stimulate contraction of the ureteral smooth muscle, which was attenuated by the presence of mirabegron. This likely occurrence is supported by previous studies which have shown that α1-antagonists can inhibit 5-HT-induced contractile responses in the bladder (Sakai et al. 2013).

We chose to perform all studies on the distal ureter as this is one of the most common sites of stone lodgement (El-Barky et al. 2014). It will be interesting to investigate if similar effects of mirabegron are present in the proximal ureter in future studies, considering it is further anatomically from the lower urinary tract. Additionally, previous studies have shown that the proximal and distal sections of the ureter respond pharmacologically differently (Lim et al. 2020), and that receptor distribution changes throughout the length of the ureter (Itoh et al. 2007). Furthermore, previous studies that have reported a relaxatory effect of β3-adrenoceptor activation by mirabegron in smooth muscles of the urinary tract showed that mirabegron could activate β1-adrenoceptors (Imran et al., 2013). To further cement that we do not believe this receptor and mechanism is involved, we demonstrated that the nitric oxide synthase inhibitor l-NNA did not alter the mirabegron-induced effects.
tract have mainly addressed contractions that are tonic in nature (Svalo et al. 2013; Takasu et al. 2007) and the role of β-adrenoceptors in phasic contractions is still underrepresented in the literature.

While there has been recent interest in trialling mirabegron as a medical expulsive therapy drug, our findings in this report suggest that the therapeutic doses utilised clinically, where maximal plasma level is approximately 83–167 nM (Krauwinkel et al. 2012), may not cause a relaxation of the ureter to improve stone passage. While we acknowledge that this should be investigated in human tissues for further validity, we suggest that the effects of mirabegron are limited to off-target effects that require high concentrations and β3-adrenoceptors might not be a significant functional target for medical expulsive therapy.

Author contribution IL and RCW conceived and designed the research. IL conducted experiments. IL contributed new reagents or analytical tools. IL and RCW analysed data. IL wrote the manuscript, while RCW edited. All authors read and approved the manuscript and all data were generated in-house and no paper mill was used.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions Iris Lim received a Faculty Early Career Research Grant (Bond University) which supported the experimental work for this study. The funding source was not involved in the study design, data collection and analysis, report writing and decision to submit the article for publication.

Data availability Raw data has been made available.

Declarations

Ethics approval The animal tissues utilised in this study were obtained from an abattoir after slaughter for food and were considered waste and therefore, did not require ethical approval by the institutional committee.

Consent to participate Not applicable.

Consent for publication Not applicable.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Alexandre EC, Kiguti LR, Calmasini FB, Silva FH, da Silva KP, Ferreira R et al (2016) Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3-adrenoceptor activation and alpha1-adrenoceptor blockade. Br J Pharmacol 173:415–428

Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP et al (2016) Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART I. J Urol 196:1153–1160

Campschroer T, Zhu XY, Vernooij RWM, Lock TMTW (2018) alpha-blockers as medical expulsive therapy for ureteric stones: a Cochrane systematic review. Bju Int 122:932–945

El-Barky E, Ali Y, Sahsah M, Terra AA, Kehinde EO (2014) Site of impaction of ureteric calculi requiring surgical intervention. Urolithiasis 42:67–73

Folaisire OS, Chess-Williams R, Sellers DJ (2017) Inhibitory effect of the urothelium/lamina propria on female porcine urethral contractility & effect of age. Clin Exp Pharmacol Physiol 44:954–960

Forman A, Andersson KE, Henriksson L, Rud T, Ulmsten U (1978) Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo. Acta Pharmacol Toxicol (copenh) 43:111–118

Gilliams K, Juliebo-Jones P, Juliebo SO, Somani BK (2021) Gender differences in kidney stone disease (KSD): findings from a systematic review. Curr Urol Rep 22:50

Huang R, Liu Y, Ciotkowska A, Tamalunas A, Waidelich R, Strittmatter F et al (2021) Concentration-dependent alpha1-adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by mirabegron in the human prostate. Front Pharmacol 12:666047

Igawa Y, Michel MC (2013) Pharmacological profile of beta3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol 386:177–183

Imran M, Najmi AK, Tabrez S (2013) Mirabegron for overactive bladder: a novel, first-in-class beta3-agonist therapy. Urol J 10:935–940

Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K (2007) Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol 14:749–753

Kang SH, McDermott C, Farr S, Chess-Williams R (2015) Enhanced urothelial ATP release and contraction following intravesical treatment with the cytotoxic drug, doxorubicin. Naunyn Schmiedebergs Arch Pharmacol 388:773–780

Krauwinkel W, van Dijk J, Schalderlee M, Eltink C, Meijer J, Strabach G et al (2012) Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 34:2144–2160

Lim I, Chess-Williams R, Sellers D (2020) A porcine model of ureteral contractile activity Influences of age, tissue orientation, region, urothelium, COX and NO. J Pharmacol Toxicol Methods 102:106661

Maki T, Kajioska S, Isumi M, Karemian E, Lee K, Shiotama T et al (2019) Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle. Low Urin Tract Symptoms 11:O209–O217

Matsumoto R, Otsuka A, Suzuki T, Shino H, Mizuno T, Kurita Y et al (2013) Expression and functional role of beta3-adrenoceptors in the human ureter. Int J Urol 20:1007–1014
Michel MC (2020) Alpha1-adrenoceptor activity of beta-adrenoceptor ligands - An expected drug property with limited clinical relevance. Eur J Pharmacol 889:173632
Michel MC, Murphy TJ, Motulsky HJ (2020) New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology. J Pharmacol Exp Ther 372:136–147
Mo W, Michel MC, Lee XW, Kaumann AJ, Molenaar P (2017) The beta3-adrenoceptor agonist mirabegron increases human atrial force through beta1-adrenoceptors: an indirect mechanism? Br J Pharmacol 174:2706–2715
Sakai T, Kasahara K, Tomita K, Ikegaki I, Kuriyama H (2013) Naftopidil inhibits 5-hydroxytryptamine-induced bladder contraction in rats. Eur J Pharmacol 700:194–200
Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K (2011) Characterization of alpha1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology 77(762):e713-767
Shen H, Chen Z, Mokhtar AD, Bi X, Wu G, Gong S et al (2017) Expression of beta-adrenergic receptor subtypes in human normal and dilated ureter. Int Urol Nephrol 49:1771–1778
Svalo J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, Bouchelouche P (2013) The novel beta3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol 699:101–105
Takahashi S, Mishima Y, Kuroishi K, Ukai M (2022) Efficacy of mirabegron, a beta3-adrenoceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int J Urol 29:7–15
Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T et al (2007) Effect of (R)-2-[(2-hydroxy-2-phenylethyl)amino]ethyl] acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647
Tang QL, Wang DJ, Zhou S, Tao RZ (2021) Mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study. World J Urol 39:4465–4470
Tasler S, Baumgartner R, Behr-Roussel D, Oger-Roussel S, Gorny D, Giuliano F, Ney P (2012) An aryloxypropanolamine b3-adrenoceptor agonist as bladder smooth muscle relaxant. Eur J Pharmacol 46:381–387
U.S. Food and Drug Administration (2012) Full prescribing information for MYRBETRIQ. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/20261s011lbl.pdf
Yamada S, Chimoto J, Shiho M, Okura T, Morikawa K, Wakuda H et al (2021) Possible involvement of muscarinic receptor blockade in mirabegron therapy for patients with overactive bladder. J Pharmacol Exp Ther 377:201–206
Zaitouna M, Alsaid B, Lebacle C, Timoh KN, Benoit G, Bessede T (2017) Origin and nature of pelvic ureter innervation. Neurourol Urodyn 36:271–279

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.